Lineage Cell Therapeutics, Inc. (LCTX) - Dilution Analysis

S-3 filing: The filing is for a shelf offering of up to $100,000,000 in any combination of common shares, preferred shares, debt securities, and warrants.

8-K filing: Lineage Cell Therapeutics, Inc. sold 12,000,000 common shares to Janus Henderson Investors at $1.75 per share, receiving $21 million in gross proceeds. ($21.0M proceeds)

10-Q filing | 228.9M shares outstanding

10-Q filing | 228.4M shares outstanding

10-Q filing | 226.1M shares outstanding

10-K filing | 228.4M shares outstanding

8-K filing: Lineage Cell Therapeutics, Inc. entered into securities purchase agreements for a registered direct offering of up to 39,473,688 common shares and warrants with unaffiliated institutional investors and Broadwood Partners, L.P. at a combined purchase price of $0.76 per share and warrant, expecting to receive approximately $30 million in gross proceeds. ($60.0M proceeds)

10-Q filing | 188.8M shares outstanding

10-Q filing | 188.8M shares outstanding

10-Q filing | 182.9M shares outstanding

10-K filing | 172.7M shares outstanding

S-3 filing: The company is filing an S-3 to register an indeterminate number of common shares, preferred shares, debt securities, and warrants, up to an aggregate initial offering price not to exceed $200,000,000, which may be sold separately or in combination.

8-K filing: Lineage Cell Therapeutics, Inc. entered into a stock purchase agreement for a registered direct offering of 13,461,540 common shares at $1.04 per share, with gross proceeds expected to be $14.0 million, with Broadwood Partners, L.P. purchasing 6,730,770 shares and Don M. Bailey purchasing approximately 100,000 shares. ($14.0M proceeds)

10-Q filing | 174.9M shares outstanding

10-Q filing | 170.6M shares outstanding

10-Q filing | 170.1M shares outstanding

10-K filing | 169.8M shares outstanding

10-Q filing | 169.8M shares outstanding

10-Q filing | 169.7M shares outstanding

10-Q filing | 169.7M shares outstanding

10-K filing | 169.7M shares outstanding

8-K filing: Lineage Cell Therapeutics, Inc. approved restricted stock units awards for an aggregate of 694,424 of the Company's common shares to certain employees, with vesting tied to continued service and the achievement of milestones under the Collaboration and License Agreement with Roche.

10-Q filing | 167.6M shares outstanding

10-Q filing | 167.5M shares outstanding

10-Q filing | 158.7M shares outstanding

S-3 filing: Locust Walk Acquisition Corp. files an S-3 form to register an indeterminate number of common shares, preferred shares, debt securities, and warrants with an aggregate initial offering price not to exceed $75,000,000.

S-3 filing: The filing covers the offer and resale of 251,835 common shares by a selling shareholder, which were issued to settle warrants related to the acquisition of Asterias Biotherapeutics.

10-K filing | 161.6M shares outstanding

8-K filing: Lineage sold 3,094,322 common shares for $5.4 million, 7,941,122 additional ATM Shares for gross proceeds of approximately $19.6 million, 2,500,000 shares of common stock of OncoCyte for gross proceeds of approximately $10.1 million and 7,400 additional HBL Shares for gross proceeds of approximately $21,000. ($35.1M proceeds)

10-Q filing | 150.0M shares outstanding

10-Q filing | 149.8M shares outstanding

10-Q filing | 149.8M shares outstanding

S-3 filing: The company is filing an S-3 to register for a potential future offering of up to $75,000,000 in various securities including common shares, preferred shares, debt securities, and warrants.

10-K filing | 149.8M shares outstanding